Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Phase 1

Completed

Conditions: Uveal Melanoma
Mucosal Melanoma
Cutaneous Melanoma

Interventions: Drug: RO7293583
Drug: Tocilizumab
Drug: Obinutuzumab
Drug: Adalimumab

First Posted Date: 2020-09-16

Last Posted Date: 2022-10-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 20

Registration Number: NCT04551352

Locations: 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 11 locations

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ocrelizumab
Drug: Antihistamine
Drug: Methylprednisolone

First Posted Date: 2020-09-16

Last Posted Date: 2025-05-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 769

Registration Number: NCT04548999

Locations: 🇮🇹
AOU Seconda Università degli Studi, Napoli, Campania, Italy
🇵🇱
COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika, Gdansk, Poland
🇵🇱
MA-LEK Clinical Sp. Z o.o., Katowice, Poland

and more 146 locations

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Phase 3

Active, not recruiting

Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Giredestrant-matched Placebo
Drug: Giredestrant
Drug: Letrozole-matched Placebo
Drug: Letrozole
Drug: Palbociclib
Drug: LHRH Agonist

First Posted Date: 2020-09-11

Last Posted Date: 2025-03-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 992

Registration Number: NCT04546009

Locations: 🇦🇺
Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia
🇦🇺
Sunshine Hospital, St Albans, Victoria, Australia
🇦🇺
Fiona Stanley Hospital - Medical Oncology, Murdoch, Western Australia, Australia

and more 259 locations

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ocrelizumab
Drug: Antihistamine
Drug: Methylprednisolone

First Posted Date: 2020-09-10

Last Posted Date: 2025-04-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 864

Registration Number: NCT04544436

Locations: 🇵🇱
Osrodek Badan Klinicznych Euromedis, Szczecin, Poland
🇵🇱
Centrum Medyczne NeuroProtect, Warszawa, Poland
🇵🇱
Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie, Warszawa, Poland

and more 118 locations

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Phase 3

Active, not recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Tiragolumab
Drug: Tiragolumab Matching Placebo
Drug: Atezolizumab
Drug: Atezolizumab Matching Placebo

First Posted Date: 2020-09-10

Last Posted Date: 2025-04-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 760

Registration Number: NCT04543617

Locations: 🇵🇹
Centro Hospitalar do Porto ? Hospital de Santo António, Porto, Portugal
🇵🇹
IPO do Porto, Porto, Portugal
🇿🇦
Eugene Marais Hospital, Pretoria, South Africa

and more 163 locations

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis, Primary Progressive

Interventions: Drug: Fenebrutinib
Drug: Ocrelizumab
Drug: Placebo matched to ocrelizumab
Drug: Placebo matched to fenebrutinib

First Posted Date: 2020-09-10

Last Posted Date: 2025-05-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 985

Registration Number: NCT04544449

Locations: 🇺🇸
Sutter East Bay Medical Foundation, Berkeley, California, United States
🇺🇸
Alabama Neurology Associates, Homewood, Alabama, United States
🇺🇸
Fullerton Neurology and Headache Center, Fullerton, California, United States

and more 184 locations

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

Phase 3

Active, not recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Cisplatin
Drug: Atezolizumab Matching Placebo
Drug: Paclitaxel
Drug: Tiragolumab Matching Placebo

First Posted Date: 2020-09-07

Last Posted Date: 2025-05-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 461

Registration Number: NCT04540211

Locations: 🇨🇳
Nan Tong Tumor Hospital, Nantong City, China
🇨🇳
Anhui Provincial Hospital, Anhui, China
🇨🇳
Anyang Tumor Hosptial, Anyang City, China

and more 65 locations

A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

Recruiting

Conditions: Solid Tumours

First Posted Date: 2020-08-27

Last Posted Date: 2025-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15000

Registration Number: NCT04529122

Locations: 🇫🇷
CHU Saint Etienne - Hôpital Nord, Saint Etienne, France
🇫🇷
Hôpital Privé de la Loire, Ramsay Saint Etienne, St Etienne, France
🇫🇷
CHI de Toulon - Hôpital Sainte Musse, Toulon, France

and more 128 locations

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Phase 1

Recruiting

Conditions: Advanced Liver Cancers

Interventions: Drug: Atezolizumab
Drug: IO-108 1800 mg
Drug: Bevacizumab 15 mg/kg
Drug: Tobemstomig 2100 mg
Drug: Tobemstomig 600 mg
Drug: Tobemstomig 1200 mg
Drug: Tiragolumab
Drug: Tocilizumab
Drug: TPST-1120
Drug: Bevacizumab 10 mg/kg
Drug: ADG126
Drug: IO-108 1200 mg
Drug: NKT2152

First Posted Date: 2020-08-24

Last Posted Date: 2025-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 518

Registration Number: NCT04524871

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇰🇷
CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of
🇫🇷
Gustave Roussy, Villejuif CEDEX, France

and more 26 locations

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Active, not recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Atezolizumab
Drug: Durvalumab
Drug: Tiragolumab

First Posted Date: 2020-08-14

Last Posted Date: 2025-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 829

Registration Number: NCT04513925

Locations: 🇧🇷
Crio - Centro Regional Integrado de Oncologia, Fortaleza, Ceará, Brazil
🇧🇷
Centro Integrado de Oncologia de Curitiba, Curitiba, Paraná, Brazil
🇧🇷
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul, Brazil

and more 178 locations

Home Terms & Conditions Privacy Policy